Welcome to our dedicated page for Faeth Therapeutics news (Ticker: FTH), a resource for investors and traders seeking the latest updates and insights on Faeth Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Faeth Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Faeth Therapeutics's position in the market.
Faeth Therapeutics (Nasdaq:FTH), formerly Sensei Biotherapeutics, changed its name and will begin trading under ticker FTH on June 16, 2026. Stockholders approved conversion of Series B preferred shares issued in the February 2026 Faeth acquisition and concurrent private placement, which raised about $200 million.
The company is advancing PIKTOR, an oral multi-node PI3K/AKT/mTOR inhibitor, with topline Phase 2 data in advanced endometrial cancer expected in the second half of 2026 and interim Phase 1b/2 data in HR+/HER2- breast cancer expected in 2027. A new executive team and refreshed board, including former FDA Commissioner Stephen M. Hahn, M.D., is in place.